When was J-ARM founded?

J-ARM was founded in 2006 and raised its 1st funding round 10 years after it was founded.

Where is J-ARM located?

J-ARM is headquartered in Osaka, Japan.

Is J-ARM a funded company?

J-ARM is a funded company, having raised an undisclosed amount across 2 funding rounds to date. The company's 1st funding round was a $***** PE round, raised on Aug 25, 2016.

When was the latest funding round of J-ARM?

J-ARM's latest funding was a $***** Seed round on Jan 26, 2023, with participation from 1 investor.

Where does J-ARM rank among its competitors?

J-ARM ranks 9th amongst 20 active competitors, of which 9 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was Gallant, which secured $18M in Jun, 2025.

Who are the top competitors of J-ARM?

J-ARM's top competitors include Gallant, Bioceltix and eQcell. Among them, Gallant secured the most recent funding round in June, 2025.

J-ARM - 2026 Company Profile, Team, Funding & Competitors

Company Details

J-Arm is developing lymphocyte therapy and stem cell therapy for dogs and cats. These treatments are used in animal hospitals, cosmetic surgery procedures, and also in immunoclinics for cancer.

Website: j-arm.biz
Email ID: *****@j-arm.com
Phone Number: +81 **********

Key Metrics

Founded Year

2006

Location

Osaka, Japan

Stage

Seed

Latest Funding Round

Seed, Jan 26, 2023, $*****

Investors

Japan Asia Investment & 3 more

Ranked

9^th among 20 active competitors

Similar Companies

Gallant & 22 more

View J-ARM's full profile

J-ARM has raised funding over 2 rounds. Its first funding round was on Aug 25, 2016. Its latest funding round was a Seed round on Jan 26, 2023 for $*****. 1 investor participated in its latest round. J-ARM has 4 institutional investors.

Here is the list of recent funding rounds of J-ARM:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 26, 2023	3960471	Seed	5238315	1242194	1763206	8213037
Aug 25, 2016	3454629	PE	4871581	6135533	6101939	Japan Asia Investment

Access funding benchmarks and valuations. Sign up today!

View details of J-ARM's funding rounds and investors

The founders of J-ARM is Kunihiko Okada.

Here are the details of J-ARM's key team members:

Kunihiko Okada: Founder & CEO of J-ARM.

View details of J-ARM's Founder profiles and Board Members

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of J-ARM include Gallant, Bioceltix and eQcell. Here is the list of Top 10 competitors of J-ARM, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Gallant 2018, Los Angeles (United States), Series B	Provider of stem cell based regenerative therapy for dogs	$61.5M	Bold Capital Partners, Digitalis Ventures ... & 13 others	56/100
2nd	Bioceltix 2017, Wroclaw (Poland), Seed	Developer of drugs for veterinary therapy	-	Infini, Leonarto	48/100
3rd	eQcell 2010, Guelph (Canada), Series A	Developer of stem cell therapies for the treatment of animals	$4.6M	Accelerator Centre, Ag Capital Canada	37/100
4th	Vetbiobank 2011, Marcy l Étoile (France), Seed	Veterinary regenerative medicine	$450K	Angelor, Health Angels Rhone-Alpes & 4 others	36/100
5th	Animal Cell Therapies 2008, San Diego (United States), Series A	Research and development of veterinary stem cell	$10.1M	Sabes Foundation	32/100
6th	RevaTis 2013, Luxemburg (United States), Funding Raised	Provider of undifferentiated muscle-derived stem	-	Noshaq, WBC Ventures	31/100
7th	Vetherapy 2015, San Francisco (United States), Seed	Provider of stem cell therapies for pets	$250K	IndieBio, EIC Fund & 1 others	30/100
8th	VetStem 2002, Poway (United States), Unfunded	Developer of vet stem cell therapy for animal health	-	-	30/100
9th	J-ARM 2006, Osaka (Japan), Seed	Developer of lymphocyte therapy and stem cell therapy for dogs and cats	-	Japan Asia Investment, Mitsubishi UFJ Capital ... & 2 others	29/100
10th	Global Stem cell Technology 2012, Evergem (Belgium), Acqui-Hired	Developer of blood-derived mesenchymal stem cells for clinical use in animals	-	-	29/100